NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $44.83 -1.49 (-3.21%) As of 02:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About PTC Therapeutics Stock (NASDAQ:PTCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$44.42▼$45.8050-Day Range$45.52▼$52.1352-Week Range$29.01▼$58.38Volume740,686 shsAverage Volume1.02 million shsMarket Capitalization$3.55 billionP/E Ratio6.90Dividend YieldN/APrice Target$65.00Consensus RatingModerate Buy Company Overview PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Read More PTC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScorePTCT MarketRank™: PTC Therapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 104th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 9 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoveragePTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is 6.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.87.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is 6.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.89.Read more about PTC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.01% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 18.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.38 Percentage of Shares Shorted8.01% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 18.34%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.05 News SentimentPTC Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for PTC Therapeutics this week, compared to 8 articles on an average week.Search Interest4 people have searched for PTCT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $254,158.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesPierre Gravier Sells 2,516 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockJuly 18, 2025 | insidertrades.comPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial ResultsJuly 21, 2025 | prnewswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.July 25 at 2:00 AM | Timothy Sykes (Ad)Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Price Target at $65.00July 20, 2025 | americanbankingnews.comWilliam Blair Issues Negative Estimate for PTCT EarningsJuly 17, 2025 | americanbankingnews.comPTCT - PTC Therapeutics Inc Ownership - MorningstarJuly 8, 2025 | morningstar.comMPTCT | PTC Therapeutics Inc. Annual Cash Flow Statement - MarketWatchJuly 4, 2025 | marketwatch.comPTC Therapeutics Inc. (PTCT) Stock Price Today - WSJJune 30, 2025 | wsj.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $45.14 at the beginning of the year. Since then, PTCT shares have increased by 0.5% and is now trading at $45.3650. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $9.19. The company's revenue was down 9.6% on a year-over-year basis. Read the conference call transcript. Who are PTC Therapeutics' major shareholders? PTC Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.80%), Harbor Capital Advisors Inc. (0.06%), Diversified Trust Co (0.02%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Eric Pauwels, Lee Scott Golden, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, Jerome B Zeldis, David P Southwell, Alethia Young, Stephanie Okey and Emma Reeve. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings5/06/2025Today7/25/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Price Target for PTC Therapeutics$65.00 High Price Target$112.00 Low Price Target$40.00 Potential Upside/Downside+43.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$6.51 Trailing P/E Ratio6.94 Forward P/E RatioN/A P/E GrowthN/ANet Income-$363.30 million Net Margins33.56% Pretax Margin36.74% Return on Equity-78.56% Return on Assets32.11% Debt Debt-to-Equity RatioN/A Current Ratio3.89 Quick Ratio3.85 Sales & Book Value Annual Sales$1.77 billion Price / Sales2.02 Cash FlowN/A Price / Cash FlowN/A Book Value($14.24) per share Price / Book-3.17Miscellaneous Outstanding Shares79,257,000Free Float74,898,000Market Cap$3.58 billion OptionableOptionable Beta0.50 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:PTCT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.